https://orcid.org/0000-0002-6826-7073
References
- US FDA . Immunogenicity Testing of Therapeutic Protein Products–Developing and Validating Assays for Anti-Drug Antibody Detection; Guidance for Industry (2019). https://www.fda.gov/media/119788/download
- European Medicines Agency . Guideline on Immunogenicity Assessment of Therapeutic Proteins (2017). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use . M4: the Common Technical Document (2016). https://www.ich.org/page/ctd
- Bourdage JS , CookCA, FarringtonDL, ChainJS, KonradRJ. An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J. Immunol. Methods327(1–2), 10–17 (2007).
- Butterfield AM , ChainJS, AckermannBL, KonradRJ. Comparison of assay formats for drug-tolerant immunogenicity testing. Bioanalysis2(12), 1961–1969 (2010).
- Chen YQ , PottanatTG, CarterQL, TrouttJS, KonradRJ, SloanJH. Affinity capture elution bridging assay: a novel immunoassay format for detection of anti-therapeutic protein antibodies. J. Immunol. Methods431, 45–51 (2016).
- Sloan JH , ConwayRG, PottanatTGet al. An innovative and highly drug-tolerant approach for detecting neutralizing antibodies directed to therapeutic antibodies. Bioanalysis8(20), 2157–2168 (2016).
- Devanarayan V , SmithWC, BrunelleRL, SegerME, KrugK, BowsherRR. Recommendations for systematic statistical computation of immunogenicity cut points. AAPS J.19(5), 1487–1498 (2017).
- Shankar G , DevanarayanV, AmaravadiLet al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal.48(5), 1267–1281 (2008).
- Gupta S , DevanarayanV, FincoDet al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J. Pharm. Biomed. Anal.55(5), 878–888 (2011).
- Hoffman D , BergerM. Statistical considerations for calculation of immunogenicity screening assay cut points. J. Immunol. Methods373(1–2), 200–208 (2011).
- Mire-Sluis AR , BarrettYC, DevanarayanVet al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Method289(1–2), 1–16 (2004).
- Zhang L , ZhangJJ, KubiakRJ, YangH. Statistical methods and tool for cut point analysis in immunogenicity assays. J. Immunol. Methods389(1–2), 79–87 (2013).